Scholarlink

Purpose <p>To assess the treatment related outcomes of patients with neuroendocrine carcinoma (NECC) of the uterine cervix and their patterns of failure.</p> Methods <p>This is a retrospective study in which patients with NECC FIGO 2009 stage I–IVA, who were treated between 2009 and 2021 at our institution were included. Patients were categorized as early (Stage I–IIA) and locally advanced stage (Stage IIB–IVA). The overall survival (OS) and patterns of relapse were studied. Univariate analysis was run to understand the effect of tumour and treatment related parameters on OS.</p> Results <p>Fifty-six (56) patients who were treated with radical intent were included. On immunohistochemistry, synaptophysin, chromogranin, CD 56 and neuron specific enolase expression was observed in 44/54 (81.5%), 29/53 (55%), 17/22 (77%) and 2/3 (67%) patients respectively. Thirteen patients presented with early stage disease and 43 patients presented with locally advanced stage disease. The 5-year OS for entire cohort was 34.5%, and for early and locally advanced NECC, the 5-year OS was 68.4% and 24.2% respectively. Twenty-six patients (46%) relapsed, of which the most common form of relapse was distant, occurring in 19/26 patients (73%). The most common site of distant relapse was liver, followed by lung and bones.</p> Conclusion <p>Patients with NECC have poor prognosis and multimodality treatment is recommended. Prospective multi centric rare tumour registries will be beneficial in assessing long term outcomes of patients with this rare histology, especially with differential IHC expression in tumours.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical Outcomes of Neuroendocrine Carcinoma of the Cervix: Institutional Audit

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月25日

查看全文
  • Prachi Mittal,
  • Ashwini Nagargoje,
  • Supriya Chopra,
  • Bharat Rekhi,
  • Ankita Gupta,
  • Jaya Ghosh,
  • Santosh Menon,
  • Kedar Deodhar,
  • Sushmita Rath,
  • Neha Mittal,
  • Amita Maheshwari,
  • Sudeep Gupta

摘要

Purpose

To assess the treatment related outcomes of patients with neuroendocrine carcinoma (NECC) of the uterine cervix and their patterns of failure.

Methods

This is a retrospective study in which patients with NECC FIGO 2009 stage I–IVA, who were treated between 2009 and 2021 at our institution were included. Patients were categorized as early (Stage I–IIA) and locally advanced stage (Stage IIB–IVA). The overall survival (OS) and patterns of relapse were studied. Univariate analysis was run to understand the effect of tumour and treatment related parameters on OS.

Results

Fifty-six (56) patients who were treated with radical intent were included. On immunohistochemistry, synaptophysin, chromogranin, CD 56 and neuron specific enolase expression was observed in 44/54 (81.5%), 29/53 (55%), 17/22 (77%) and 2/3 (67%) patients respectively. Thirteen patients presented with early stage disease and 43 patients presented with locally advanced stage disease. The 5-year OS for entire cohort was 34.5%, and for early and locally advanced NECC, the 5-year OS was 68.4% and 24.2% respectively. Twenty-six patients (46%) relapsed, of which the most common form of relapse was distant, occurring in 19/26 patients (73%). The most common site of distant relapse was liver, followed by lung and bones.

Conclusion

Patients with NECC have poor prognosis and multimodality treatment is recommended. Prospective multi centric rare tumour registries will be beneficial in assessing long term outcomes of patients with this rare histology, especially with differential IHC expression in tumours.